Herbal Drug Discovery for the Treatment of Nonalcoholic Fatty Liver Disease

Publication date: Available online 10 December 2019Source: Acta Pharmaceutica Sinica BAuthor(s): Tingting Yan, Nana Yan, Ping Wang, Yangliu Xia, Haiping Hao, Guangji Wang, Frank J. GonzalezAbstractFew medications are available for meeting the increasing disease burden of nonalcoholic fatty liver disease (NAFLD) and its progressive stage, nonalcoholic steatohepatitis (NASH). Traditional herb medicines (THM) have been used for centuries to treat indigenous people with various symptoms but without clarified modern-defined disease type and mechanisms. In modern times, NAFLD was defined as a common chronic disease leading to more studies to understand NAFLD/NASH pathology and progression. THM have garnered increased attention for providing therapeutic candidates for treating NAFLD. In this review, a new model called “multiple organs-multiple hits” is proposed to explain mechanisms of NASH progression. Against this proposed model, the effects and mechanisms of the frequently-studied THM-yielded single anti-NAFLD drug candidates and multiple herb medicines among which silymarin and berberine are already under U.S. FDA-sanctioned phase 4 clinical studies. Furthermore, experimental designs for anti-NAFLD drug discovery from THM in treating NAFLD are discussed. The opportunities and challenges of reverse pharmacology and reverse pharmacokinetic concepts-guided strategies for THM modernization and its global recognition to treat NAFLD are highlighted. Increasing mechanistic ...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research

Related Links:

Simon et  al1 recently published a report in Clinical Gastroenterology and Hepatology on their findings from a prospective cohort study of 361 adults with biopsy-confirmed nonalcholic fatty liver disease (NAFLD). Their study evaluated the relationship between daily aspirin use and risk for fibrosis progress ion defined by using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score, and aspartate aminotransferase-to-platelet ratio indices). They concluded that daily aspirin use was associated with less severe histologic features of NAFLD and nonalcoholic steatohepatitis and lowe r risk for prog...
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
This study aimed to assess whether fasting C-peptide represented a risk factor forNAFLD.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Authors: Michel M, Schattenberg JM PMID: 31933385 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
The microbiome exerts essential functions in health and disease, modulating key processes in metabolism, inflammation and immunity. Recent evidence has revealed a key role of the microbiome in carcinogenesis as well as anti-cancer immune responses in mouse models and patients. Herein, we will review functions of the gut microbiome in hepatocellular carcinoma (HCC), the third leading cause of worldwide cancer mortality. The majority of HCC develops in patients with chronic liver disease, caused by viral hepatitis, non-alcoholic fatty liver disease (NAFLD) and alcohol-related fatty liver disease.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Review Source Type: research
Authors: Bellan M, Rigamonti C, Giacomini GM, Makmur G, Marconi C, Nicosia F, Panero A, De Benedittis C, Burlone ME, Minisini R, Pirisi M Abstract The severity of fatty liver at ultrasound has been associated with QT length, a finding invoked to explain the excess cardiovascular risk of patients with fatty liver. However, the ability of ultrasound to stage accurately the severity of fatty liver is limited, with fibrosis a major confounder. Here, we aimed to verify the alleged relationship between fat liver content and QT length using a technique apt at discriminating steatosis from fibrosis noninvasively, i.e., tra...
Source: Gastroenterology Research and Practice - Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research
Assessing for the presence of non–alcoholic steatohepatitis (NASH) and the presence of advanced fibrosis is vital among patients with non–alcoholic fatty liver disease (NAFLD) as each is predictive of disease outcomes. A liver biopsy is the gold standard method for doing so but is impossible to perform among all patients with NAFLD. Reliable methods for noninvasively detecting for the presence of NASH and advanced fibrosis are thus a pressing need. The search for noninvasive tests has been more successful for advanced fibrosis than for NASH. Clinical prediction models and elastography have acceptable accuracy f...
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: CLINICAL REVIEWS Source Type: research
ConclusionsPMRWE and PMRPWE alleviated NAFLD through promoting mitochondrial β oxidation by enhancing liver CPT1A activity. Stilbenes (including TSG, polydatin and resveratrol) and anthraquinones (including physcion, emodin and rhein) may be the main active compounds contributing to the lipid-lowering activity provided by PMRWE and PMRPWE.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: Sakamoto Y, Oniki K, Kumagae N, Morita K, Otake K, Ogata Y, Saruwatari J Abstract Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases. Obesity is the most common and well-established risk factor for NAFLD, but there are large interindividual differences in the relationship between weight status and the development of NAFLD. Beta-3-adrenergic receptor (ADRB3) plays a key role in the development of visceral obesity and insulin resistance; however, the effect of ADRB3 polymorphisms on the risk of NAFLD remains unclear. We investigated whether or not a common rs4994 pol...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Authors: Hu DS, Zhu SH, Li X, Chen QF, Lin CJ, Fang DH, Wu JS Abstract Purpose: Limited studies have preliminarily identified a positive association between nonalcoholic fatty liver disease (NAFLD) and hemoglobin glycation index (HGI). However, this association has not been fully established. We aim to investigate the association between NAFLD and HGI in Chinese nondiabetic individuals and to construct a risk score based on HGI to predict a person's risk of NAFLD. Methods: After strict exclusion criteria, 5,903 individuals were included in this retrospective cross-sectional study. We randomly selected 1,967 sub...
Source: Canadian Journal of Gastroenterology - Category: Gastroenterology Tags: Can J Gastroenterol Hepatol Source Type: research
Authors: Azzaroli F, Mazzella G, Marchesini G, Brodosi L, Petroni ML Abstract INTRODUCTION: Fatty liver is rather common in pregnancy, occurring in two totally different conditions, i.e, nonalcoholic fatty liver disease (NAFLD) in pregnancy and acute fatty liver of pregnancy (AFLP). The former is a common condition, resulting by chance association because of the epidemics of obesity and the older age of many pregnant women in Western countries; the latter is a rare disease whose pathophysiology is still incompletely understood.Areas covered:We reviewed the evidence-based knowledge on fatty liver in/of pregnancy. Fo...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
More News: Cancer & Oncology | Complementary Medicine | Drugs & Pharmacology | Fatty Liver Disease (FLD) | Herbs | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Pathology | Study | Turmeric | Urology & Nephrology